Navigation Links
Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
Date:12/11/2012

medicines and solutions in five distinct therapeutic areas: Neuroscience, Oncology, Immunology, Infectious Diseases and Vaccines, and Cardiovascular and Metabolism. For more information about Janssen Research & Development, LLC visit www.janssenrnd.com.

Janssen Research & Development is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.  Driven by our commitment to patients, we work together to bring innovative ideas, products, services and solutions to address serious unmet medical needs around the world.

About Janssen Biotech, Inc.

Janssen Biotech, Inc. redefines the standard of care in immunology, oncology, urology and nephrology.  Built upon a rich legacy of innovative firsts, Janssen Biotech has delivered on the promise of new treatments and ways to improve the health of individuals with serious disease. Beyond its innovative medicines, Janssen Biotech is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates and health care professionals have access to the latest treatment information, support services and quality care. For more information on Janssen Biotech, Inc. or its products, visit www.janssenbiotech.com.

Janssen Biotech, Inc. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson, dedicated to addressing and solving some of the most important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we work together to bring innovative ideas, products, services and solutions to people throughout the world.  Follow us on Twitter at www.twitter.com/JanssenUS.

(This press release contains "forward-looking statements" as defined in the Pr
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
2. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
3. Landauer, Inc. Reports Fiscal 2012 Fourth Quarter And Year End Results
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
6. American Pacific to Release Financial Results and Hold Fiscal 2012 Year-End and Fourth Quarter Investor Teleconference
7. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
8. The Female Health Company Reports Record Fourth Quarter and FY2012 Operating Results
9. ObeTherapy Announces the Publication of Results Obtained with one of its Lead Compounds on a New Target for the Treatment of Obesity and Type II Diabetes
10. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
11. Landauer, Inc. Sets Date And Time For Announcement Of Fiscal Fourth Quarter And Full Year 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... TAMPA, Fla. , July, 29  2014 ... it has hired John Bournas as ... who announced plans to leave the Society last ... with extensive competencies in the healthcare association industry ... to the Society a clear vision for the ...
(Date:7/29/2014)... LAUDERDALE, Fla. , July 29, 2014 /PRNewswire-iReach/ ... medical service provider, has launched its Medical ... Program.  These services are tailored to the ... excellent standards prompted industry operators to propose that ... MHG Medical,s new program is intended to ...
(Date:7/29/2014)... 29, 2014 According to a ... Trauma Fixation Devices Market - Global Forecast, Market Share, ... global orthopedic trauma fixation devices market is estimated at ... grow at a CAGR of 7.2% from 2014 to ... billion in 2020. Browse the Orthopedic Trauma ...
Breaking Medicine Technology:ISPE Hires Healthcare Association Exec as CEO 2ISPE Hires Healthcare Association Exec as CEO 3MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4
... 2007 /PRNewswire-USNewswire/ -- The,following statement may be attributed ... Medical Research (CAMR): , "In the face of ... the stroke of his veto pen deliberately to ... well as endanger,the future health and well being ...
... - Elixir,Pharmaceuticals, Inc., announced today the publication ... (mitiglinide calcium,hydrate) monotherapy, or combination therapy with ... meals. The data were,published in the Abstract ... Scientific Sessions in Chicago, Illinois.,Glufast is an ...
Cached Medicine Technology:President Bush Ignores America's Plea for Support of Stem Cell,Research 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 3Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 4Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 5
(Date:7/29/2014)... the nation,s largest interdisciplinary organization devoted to ... Bowers, PhD, RN, FAAN, of the University of Wisconsin-Madison ... Minority Issues in Gerontology Outstanding Mentorship Award. , This ... has exemplified outstanding commitment and dedication to mentoring minority ... presentation will take place at GSA,s 67th Annual Scientific ...
(Date:7/29/2014)... the nation,s largest interdisciplinary organization devoted to the ... PhD, of Cornell University as the 2014 recipient of ... in Behavioral and Social Gerontology. , This distinguished honor, ... and social gerontology. Individuals who have received their doctorate ... is given by GSA in conjunction with the Margret ...
(Date:7/29/2014)... The report “Filling Equipment Market by Industry (Food, ... Weight), Process (Manual, Semi-Automatic, Automatic), Product (Solid, Semi-Solid, ... to 2019”, defines the filling equipment market and ... segments with analyses and projections of the market ... of value. It also identifies the driving and ...
(Date:7/29/2014)... ENCINITAS, Calif. (PRWEB) July 29, 2014 ... prescription drug abuse directly at the source? That’s the ... , an innovative prescription drug abuse risk program developed ... from hundreds of applicants worldwide to be part of ... September 10-12 in San Francisco, CA. The Hive is ...
(Date:7/29/2014)... INDIANAPOLIS -- With the increasing use of electronic ... a growing demand for a computerized version of ... United States. In a new study, researchers from ... Regenstrief Institute report that substantial work lies ahead ... Future,s guidelines into computerized prompts for physicians, but ...
Breaking Medicine News(10 mins):Health News:Bowers to receive GSA's 2014 Minority Mentorship Award 2Health News:Löckenhoff earns GSA's 2014 Baltes Foundation Award 2Health News:Filling Equipment Market worth $8 Billion by 2019 - Report by MarketsandMarkets 2Health News:Filling Equipment Market worth $8 Billion by 2019 - Report by MarketsandMarkets 3Health News:Filling Equipment Market worth $8 Billion by 2019 - Report by MarketsandMarkets 4Health News:SafeUseNow Selected to Showcase at TEDMED Hive 2014 2Health News:SafeUseNow Selected to Showcase at TEDMED Hive 2014 3Health News:Study: Pediatric preventive care guidelines need retooling for computerized format 2Health News:Study: Pediatric preventive care guidelines need retooling for computerized format 3
... chronically exposed to family turmoil, violence, noise, poor housing ... strain// than other young people. ,However, when ... these negative physiological changes, reports a new study from ... that the cardiovascular systems of youths who are exposed ...
... cancer is so much more prevalent in men than women: ... in men than women plays a role in the development ... new types of treatment with the disease. ,In ... Chawnshang Chang, Ph.D., of the University of Rochester Medical Center ...
... stent therapy and bypass surgery for coronary artery disease ... event within 30 days after the procedures// , according ... similar outcomes three years after treatment. Patients with coronary ... bypass surgery to reroute the arteries' blood flow or ...
... the carotid artery by dental x-rays is not enough evidence ... a review published in the Journal of the American Dental ... leading causes of death and disability among adults in the ... and nutrients to the brain bursts or becomes clogged by ...
... head and neck cancer that targets multiple peptides (parts ... tumors. ,The researchers created the vaccine ... is mutated in most cancers and associated with poor ... also expresses unaltered, or "wild-type," p53 peptides in tumors. ...
... a dermatologist has a higher survival rate than by a ... to detect// the tumor in its early stages which can ... ,Individuals whose melanoma is diagnosed by a dermatologist may be ... years than those with melanoma diagnosed by a non-dermatologist, according ...
Cached Medicine News:Health News:Adolescents Exposed to Family Turmoil and Violence Face Stress-related Problems 2Health News:Scientists Find Clue for the Prevalence of Bladder Cancer More in Men 2Health News:Scientists Find Clue for the Prevalence of Bladder Cancer More in Men 3Health News:Scientists Find Clue for the Prevalence of Bladder Cancer More in Men 4Health News:Bypass Surgery, Drug-eluting Stents Possess Similar Risk and Outcome 2Health News:Dental X-rays of Carotid Artery Cannot Estimate Stroke Risk 2Health News:Head and Neck Cancer Vaccine Targets Proteins to Create Immune Response 2Health News:Chances of Survival for Melanoma is High When Detected by Dermatologists 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: